Australian researchers closer to finding better vc by Emo_CutE_GiRl_ 2014/06/15 12:58
Australian researchers closer to finding better vaccines for diabetes patients
Australian researchershave said they are a step closer to establishing a link between a protein and type-1 diabetesthat may help in development of better vaccinesto potentially treat and prevent the disease.
The research shows that how a protein, called GAD65, changes its shape when it turns itself on and off. This characteristic may also link it to type-1 diabetes.
In the human brain, GAD65performs an essential role: it makes "neurotransmitters" - chemicals that pass messages between brain cells. GAD65is also found in the pancreas.
Previous studies linked it to type-1 diabetesbecause the body makes antibodies against the protein.
However, the molecular details of what makes GAD65"sticky" to antibodies has remained a mystery until now.
The new research, led by Melbourne-based Monash1 University, investigated how GAD65regulates the production of neurotransmittersby changing its shape.
The findings, published in the journal PNAS, showed that the normal function of the protein may come at a price, said Principal Investigator Ashley Buckle from the School of Biomedical sciences.
Australian researchers closer to finding better vaccines for diabetes patients
Australian researchershave said they are a step closer to establishing a link between a protein and type-1 diabetesthat may help in development of better vaccinesto potentially treat and prevent the disease.
The research shows that how a protein, called GAD65, changes its shape when it turns itself on and off. This characteristic may also link it to type-1 diabetes.
In the human brain, GAD65performs an essential role: it makes "neurotransmitters" - chemicals that pass messages between brain cells. GAD65is also found in the pancreas.
Previous studies linked it to type-1 diabetesbecause the body makes antibodies against the protein.
However, the molecular details of what makes GAD65"sticky" to antibodies has remained a mystery until now.
The new research, led by Melbourne-based Monash1 University, investigated how GAD65regulates the production of neurotransmittersby changing its shape.
The findings, published in the journal PNAS, showed that the normal function of the protein may come at a price, said Principal Investigator Ashley Buckle from the School of Biomedical sciences.
Emo_CutE_GiRl_ 2014/06/15 13:00
"GAD65 has an unpredictable, almost Jekyll and Hyde personality when it is turned on and off. When active and making neurotransmitters, it is rigid and rather motionless," Buckle said.
"Ironically, when switched off, rather than resting as you might expect, it becomes mobile, dancing and jiggling around. We suspected that this dual personality might affect how antibodies 'see' it," he said.
"This turns out to be true - antibodies interact with it very differently depending on whether it's on or off," Buckle said.
GAD65 has previously been used in clinical trials as a vaccine for type-1 diabeteswith limited success.
Buckle said the discovery may ultimately lead to the development of better vaccinesto potentially treat and prevent type-1 diabetes.
"The idea to immunise an individual with GAD65to help the immune system develop a tolerance against it, to stop or at least dampen the immune reaction is a good one. But so far these attempts have not been very successful. This research could change that," Buckle said.
The seven-year study used a combination of experimental and computational methods to understand what GAD65looks like in its 'off' state and how human antibodies interact with both forms.
"GAD65 has an unpredictable, almost Jekyll and Hyde personality when it is turned on and off. When active and making neurotransmitters, it is rigid and rather motionless," Buckle said.
"Ironically, when switched off, rather than resting as you might expect, it becomes mobile, dancing and jiggling around. We suspected that this dual personality might affect how antibodies 'see' it," he said.
"This turns out to be true - antibodies interact with it very differently depending on whether it's on or off," Buckle said.
GAD65 has previously been used in clinical trials as a vaccine for type-1 diabeteswith limited success.
Buckle said the discovery may ultimately lead to the development of better vaccinesto potentially treat and prevent type-1 diabetes.
"The idea to immunise an individual with GAD65to help the immune system develop a tolerance against it, to stop or at least dampen the immune reaction is a good one. But so far these attempts have not been very successful. This research could change that," Buckle said.
The seven-year study used a combination of experimental and computational methods to understand what GAD65looks like in its 'off' state and how human antibodies interact with both forms.
#2 General Area
A forum for life in general. Post about news, social matters, relationships, lifestyle, or anything on your mind.